Products
Frovatriptan is commercially available in the form of film-coated tablets (Menamig). It has been approved in many countries since 2004.
Structure and properties
Frovatriptan (C14H17N3O, Mr = 243.3 g/mol) is present in drugs as frovatriptan succinate monohydrate, a white powder that is soluble in water. It is an indole derivative and structurally related to serotonin.
Effects
Frovatriptan (ATC N02CC07) has vasoconstrictive, analgesic, and anti-inflammatory properties. The effects are due to selective binding to 5-HT1B and 5-HT1D serotonin receptors.
Indications
For the treatment of acute migraine with or without aura.
Dosage
According to the SmPC. During treatment, the low maximum daily dose (5 mg) and dosing interval (at least 2 hours) must be observed. Frovatriptan should be taken as soon as possible after the onset of the attack but not as a preventive measure.
Contraindications
- Hypersensitivity
- Certain cardiovascular diseases
- Severe hepatic insufficiency
- Frovatriptan must not be combined with ergot alkaloids and other triptans.
For complete precautions, see the drug label.
Interactions
Frovatriptan is metabolized by CYP1A2. Drug-drug interactions are possible with ergot alkaloids, triptans, drugs with serotonergic properties (risk of serotonin syndrome), MAO inhibitors, and oral contraceptives.
Adverse effects
The most common possible adverse effects include dizziness, fatigue, tingling, headache, and flushing.